Given the shift towards adjuvant and neoadjuvant immunotherapy for the treatment of melanoma, a critical understanding of the tumor microenvironment (TME) within the skin is required to inform new therapeutic combinations with anti-PD-1. The gene discussed is PDCD1; the disease is neoplasm.